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Abstract We previously reported that NGR-fused
IFN-a2a (IFN-a2a-NGR) exhibited similar biological
activities with native IFN-a2a and was well-tolerated
in mice, rats and monkeys. In the current study, we
evaluated the mechanisms of this fusion protein on
angiogenesis and tumor formation. Our data indicated
that IFN-a2a-NGR has the ability to target tumor
blood vessels while preserving the original function of
native IFN-a2a. IFN-a2a-NGR was found to be
concentrated in the tumor tissues, particularly around
the vessel areas. In contrast to IFN-a2a, IFN-a2a-
NGR significantly decreased microvessel density and
increased the apoptosis of vascular endothelial cells.
IFN-a2a-NGR also decreased the expression of VEGF
and bFGF in tumor cells. Significant inhibition of
invasion, migration, tube formation and induction of
apoptosis of endothelial cells were observed in IFN-
a2a-NGR-treated group. In conclusion, results from
in vitro and in vivo experiments indicate that IFN-a2a-
NGR is a promising anti-angiogenic agent with greater
therapeutic efficacy than IFN-a2a.
Keywords IFN-a2a-NGR  Tumor-targeted IFN-
a2a  Anti-tumor activity  NGR peptide  Tumor
neovessels
Introduction
Interferon-alpha2a (IFN-a2a) is a multifunctional cyto-
kine that has anti-viral, immunomodulatory and anti-
tumor effects (Petska et al. 1987).The anti-tumor effects
of IFN-a2a are mediated through upregulation of
surface expression ofmajor histocompatibility complex
(MHC) class I molecules, enhancement of the
Weina Li and Qiang Hao have contributed equally to this
article.
Electronic supplementary material The online version of
this article (doi:10.1007/s10616-014-9743-y) contains supple-
mentary material, which is available to authorized users.
W. Li  Q. Hao  L. He  J. Meng  M. Li 
X. Xue  C. Zhang  W. Zhang  Y. Zhang
The State Key Laboratory of Cancer Biology, Department
of Biopharmaceutics, School of Pharmacy, Fourth
Military Medical University, Xi’an 710032,
People’s Republic of China
H. Li
Laboratories of Respiratory Biology, National Institute of
Environmental Health Sciences, National Institutes of
Health, Research Triangle Park, NC 27709, USA
W. Zhang (&)  Y. Zhang (&)
Department of Biopharmaceutics, School of Pharmacy,
The Fourth Military Medical University, 17 Changle West







proliferation of type-I helper T cells (Th1) (Belardelli
1995) and generation of cytotoxic T lymphocytes
(CTLs) in specific antitumor immune responses (von
Hoegen et al. 1990). IFN-a2a has also been shown to
inhibit of cell growth and antiangiogenesis (Okada et al.
2001) and directly inhibit the release of tumor-derived
pro-angiogenic factors such as VEGF and bFGF (von
Marschall et al. 2003; Singh et al. 1995).
Because of its various therapeutic properties, IFN-a
therapy has been approved worldwide for the treat-
ment of various malignancies and virological diseases,
such as hairy cell leukemia, melanoma, and renal cell
carcinoma (Rios et al. 1985). However, IFN-a2a
therapy is associated with significant toxicities,
including severe neuropsychiatric, hematologic and
hepatic effects (Jonnasch and Haluska 2001).
Several tumor-homing peptides, such as the cyclic
peptide, NGR (CNGRCVSGCAGRC), have been
found in vivo and were used in combination with
anti-cancer drugs to increase the anti-tumor activity of
these drugs and reduce the toxicity to normal tissues
(Arap et al. 1998; Sacchi et al. 2004;Wang et al. 2006).
In previous studies, we constructed the fusion
protein IFN-a2a-NGR. We coupled an NGR-contain-
ing peptide (GNCNGRCVSGCAGRC) with the C-ter-
minal of IFN-a2a and expressed the fusion protein in
E. coli. Purification was achieved via ion exchange
chromatography (Meng et al. 2007). Preclinical safety
studies revealed that IFN-a2a-NGRwas well tolerated
at pharmacologically active doses in mice, rats and
monkeys (Meng et al. 2008).
Here, we further investigate the effects of this
fusion protein on tumor growth and anti-angiogenic
activity. Our data indicated that IFN-a2a-NGR has a
greater inhibitory effect on the growth of tumors
compared to that of IFN-a2a. IFN-a2a-NGR increased
the anti-tumor activity of IFN-a2a and lowered the
dosage required for this effect. Our findings indicated
that IFN-a2a-NGR mediated its anti-tumor effects by
decreasing pro-angiogenic factors and inhibiting the
function of vascular endothelial cells.
Materials and methods
Animals
Healthy female nude mice (4–6 weeks old) were
purchased from the Institute of Pharmaceutical
Research Animal Resource of Shanghai and main-
tained under institutional animal care protocols.
Cell culture
A549 (human lung cancer cell line) and SPC-A-1
(human lung cancer cell line) cells were cultured in
RPMI 1640 (Gibco, Grand Island, NY, USA). Human
umbilical vein endothelial cells (HUVEC)were cultured
inDMEM(Gibco) supplementedwith 10 % fetal bovine
serum (Hyclone, Logan, UT, USA), 2 mM glutamine,
100 U/mL penicillin and 100 mg/L streptomycin. All
cells were maintained at 37 C in a 5 % CO2 incubator.
All cell lines were purchased from the National Rodent
Laboratory Animal Resource (Shanghai, China).
Expression and purification of IFN-a2a-NGR
The IFN-a2a-NGR was purified and prepared as
previously reported (Meng et al. 2007). In brief,
IFNa2a-NGR was produced by a strain of Escherichia
coli bearing a genetically engineered plasmid that
contains the IFNa2a-NGR gene and was purified to
homogeneity by a combination of Q-Sepharose and
SP-Sepharose fast-flow chromatography.
Tumor implantation and anti-tumor studies in vivo
A549 or SPC-A-1 cells (1 9 107 cells/mouse) were
injected subcutaneously into healthy nude mice.
10 days after transplantation, as the mean size of the
tumors was about 0.4 cm in diameter, mice with size-
matched tumors were randomized into seven treatment
groups (n = 8): 0.9 % sodium chloride group, low dose
(LD) IFN-a2a-NGR group (1 9 106 IU/kg), middle
dose (MD) IFN-a2a-NGR group (3 9 106 IU/kg), high
dose (HD) IFN-a2a-NGR group (9 9 106 IU/kg),
LD IFN-a2a group (1 9 106 IU/kg), MD IFN-a2a
group (3 9 106 IU/kg) and HD IFN-a2a group
(9 9 106 IU/kg). The purified IFN-a2a was pur-
chased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA; sc-4623). All drugs, diluted with 0.9 %
sodium chloride, were administered i.p. once a day.
Animals were sacrificed when the tumors reached
1.8–2.0 cm in diameter and the inhibition rates of the
growth of A549 or SPC-A-1 xenografted tumors were
calculated according to the formula: inhibition rate
(%) = (1 - tumor weight in test group/tumor weight
in control group) 9 100.
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ELISA assay
The microtiter plates were coated with purified
recombinant human CD13 at 1 lg/well (Sino Biolog-
ical Inc, Beijing, China) at 4 C overnight. Plates were
then washed with PBS containing 0.1 %Tween 20 and
the remaining protein-binding sites were blocked with
PBS containing 0.1 % Tween 20 and 5 % non fat dry
milk prior to the addition of serially diluted IFN-a2a-
NGR or IFN-a2a at RT for 2 h. Plates were then
washed and the bound IFN-a2a-NGR or IFN-a2a was
detected using an anti-hIFN-a monoclonal antibody
(Abcam, Cambridge, UK). The reaction was devel-
oped with o-phenylenediamine as the substrate and
measured with a Bio-Rad ELISA reader (OD490)
(Hercules, CA, USA).
Total RNA extraction and Real-time PCR
Total RNA from tumors were isolated using Trizol
reagent (Invitrogen Life Technologies, Carlsbad, CA,
USA) according to the manufacturer’s instructions.
First-strand complementary DNA synthesis was per-
formed using the cDNA RT Kit (Takara, Otsu, Shiga,
Japan). Portions of double-stranded cDNA were
subjected to PCR with a SYBR Green PCR Reagents
kit (Applied Biosystems, Foster City, CA, USA). PCR
was performed at 95 C for 15 min, followed by 35
cycles of (95 C for 20 s, 56 C for 30 s, 72 C for
30 s), followed by 72 C for 1 min. The following




50-AAAGTATAGCTTTCTGCC-30; and b-actin for-
ward 50-GGCACCACACCTTCTACA-30, reverse 50-
AGGAAGGCTGGAAGAGTG-30. Incorporation of
the SYBR Green dye into PCR products was moni-
tored using an ABI Prism 7700 sequence detection
system. The comparative threshold cycle (CT) method
(DDCT) was used for relative quantification of gene
expression.
Immunohistochemistry
Mouse tumor tissues were fixed in 10 % neutral
buffered formalin for 3–6 h, maintained in 50 mmol
PBS (pH 7.2) containing 5 % sucrose overnight and
embedded in paraffin. Tissue sections (5 lm)were then
mounted on glass slides according to themanufacturer’s
instructions. The endogenous peroxidase activity was
quenched by incubation of sections in 50 %/50 %
solution of 3 % hydrogen peroxide and absolute meth-
anol. Antigen retrieval was performed using 1 mM
EDTA (ethylenediamine-tetra acetic acid), pH 8.0, in
steamer for 30 min. The section was incubated with
mouse anti-human VEGF (sc-152, Santa Cruz Biotech-
nology Inc, Santa Cruz, CA, USA) and anti-human
bFGF (sc-79, Santa Cruz Biotechnology Inc) monoclo-
nal antibody at 4 C overnight and at 37 C for 60 min;
and this was followed by incubation with a biotinylated
secondary antibody (BOSTER, Wuhan, China) and
biotin-peroxidase complex (BOSTER). Finally, the
sections were counterstained with hematoxylin.
Western blot
Tumor tissues from A549 bearing-mice treated with
IFN-a2a-NGR or IFN-a2a were obtained from anti-
tumor studies. The tissues were homogenated in lysis
buffer and then the protein concentration was mea-
sured by the bicinchoninic acid kit (CWBIO, Beijing,
China). 40 lg per band of total protein were used to
normalize the Western blots. The membrane was
incubated with the anti-mouse-bFGF (sc-152, Santa
Cruz Biotechnology Inc), anti-mouse-VEGF
(1H12L17, Zymed Laboratories, San Francisco, CA,
USA) antibodies for 2 h at RT and followed by
incubation with specific HRP-conjugated secondary
antibodies (Beijing Zhongshan Company, China) for
half an hour. The immunoreactive protein was visu-
alized with an enhanced chemiluminescence,
(KGP1123, Nanjing keygen Company, China).
TUNUL assay
DNA fragmentation induced in vascular endothelial
cells by IFN-a2a-NGR or IFN-a2a treatment for 72 h
was measured using the TUNEL assay (Roche
Molecular Biochemicals, Mannheim, Germany) fol-
lowing the manufacturer’s instruction. Cells were
fixed with 4 % paraformaldehyde (Sigma chemicals,
St Louis, USA) solution in PBS for 1 h at room
temperature and rinsed with PBS, treated with 0.3 %
H2O2-methanol solution, and then permeabilized with
0.25 % Triton X-100 at 4 C for 2 min. The broken
DNA ends of vascular endothelial cells were labeled
with TdT and fluorescein-dUTP for 60 min at 37 C.
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Detection of microvessel density
Paraffin-embedded sections were incubated with a
monoclonal mouse anti-human CD34 antibody (Clone
QBEnd/10, Neomarkers, Fremont, CA, USA) at 4 C
overnight. A positive reaction was visualized using 3,
3-diamino-benzidine as the chromagen (DAB sub-
strate kit; Vector Laboratories Inc., Burlingame, CA,
USA). Vessel density was determined by counting the
number of microvessels per high-power field, as
described previously (Li et al. 2011).
Matrigel tube formation assay, migration assay
and invasion assay
Matrigel (Collaborative Biomedical, Bedford, MA,
USA) was added (250 lL) to each well of a 24-well
plate and was left to polymerize at 37 C for 1 h.
HUVECs were seeded onto the plate at a density of
50,000 cells per well and treated with conditioned
medium (containing half of the 0.2 lm filtered
medium in which the lung cancer cells have been
previously grown for 24 h and IFN-a2a or IFN-a2a-
NGR) at 37 C for 8 h. Tube formation was then
observed using an inverted phase-contrast microscope
(Nikon Corporation, Tokyo, Japan). Images were
captured with a video graphic system (Optronics,
Goleta, CA). Each experiment was repeated for three
times. For migration assays, HUVECs were seeded
onto the upper wells of a Millicell Insert (Millipore,
Billerica, MA, USA) in conditioned medium contain-
ing IFN-a2a-NGR or IFN-a2a and incubated for 24 h
at 37 C. Cell migration was measured by counting the
number of migrated cells in five random non-over-
lapped fields at 100 9 magnification. Invasion assays
were performed as described previously (Bonaccorsi
et al. 2000). Migrated cells were quantitated by
counting cells and representative images were taken
using an IX70 microscope (Olympus, Tokyo, Japan)
equipped with brightfield optics (2009).
Scratch assay
The scratch assay was performed by plating cells in
6-well dishes. HUVECs were cultured in endothelial
cell medium with 5 % FBS. After reaching 80 %
confluence, a scratch was made through the culture
dish with a sterile plastic micropipette tip to generate
one homogeneous wound along each well. After
wounding, the displaced cells were removed with
two PBS washes. Cells were further incubated with or
without IFN-a2a-NGR or IFN-a2a for 36 h and the
images were taken under a microscope using an ocular
grid. Three wounds were sampled for each treatment.
The relative wound area was calculated as described
before (Deng et al. 2006).
Statistical analysis
Statistics were carried out with the SPSS version 11.0
(SPSS Inc., Chicago, USA). Calculations were per-
formed using the Student’s t test or v2 test where
appropriate. Differences were considered significant
when the p value was\0.05.
Results
Anti-tumor activity of IFN-a2a-NGR
To evaluate the bioactivity of IFN-a2a-NGR, we
assessed its effects on tumor growth in the A549 or
SPC-A-1 tumor-bearing nude mice in vivo. Pictures of
isolated tumors are shown in Fig. 1c. Treatment with
IFN-a2a-NGR resulted in a significant reduction in
tumor weight in comparison with the IFN-a2a-treated
group (Fig. 1a, b). Moreover, the anti-tumor activity
of IFN-a2a-NGR at MD was similar or higher than
that of IFN-a2a at HD, and the anti-tumor activity of
IFN-a2a-NGR at LD was similar or higher than that of
IFN-a2a at MD, suggesting that IFN-a2a-NGR was
more effective in reducing tumor size in vivo.
IFN-a2a-NGR can selectively bind to vessels
of tumor tissues and decrease microvessel density
(MVD)
As shown in Fig. 2a, 3 9 106U/kg IFN-a2a-NGR or
IFN-a2a was injected to tumor-bearing mice i.v.
30 min later, mice were sacrificed and tumor tissue
sections were stained with mouse anti-hIFNa mono-
clonal antibody. The tumor sections from the IFN-
a2a-NGR treated group showed strong staining,
whereas those from the negative control and IFN-
a2a treated groups showed weak staining with anti-
human IFN-a antibody. The tumor vessels targeting
property of IFN-a2a-NGR conjugates may therefore
contribute to the accumulation of IFN-a2a-NGR in the
1042 Cytotechnology (2015) 67:1039–1050
123
tumor tissue. As contrast, non-tumor targeted IFN-a2a
showed remarkably lower concentration in tumor than
IFN-a2a-NGR. Besides, the tumor tissues obtained
from IFN-a2a-NGR-treated mice had a markedly
higher accumulation of drugs that were localized
around the tumor vessels and the surrounding areas. In
addition, the binding affinity of IFN-a2a-NGR or IFN-
a2a to hCD13 was assessed. As shown in Fig. 2b, the
binding affinity between IFN-a2a-NGR and CD13
increased in a dose-dependent manner, while IFN-a2a
displayed a lack of affinity to CD13. The binding of
CD13 and IFN-a2a-NGR could be neutralized by both
an anti-CD13 antibody and free NGR peptide (Figure
S1). Figure 2c shows that there were new vessels of
Fig. 1 Anti-tumor effect of IFN-a2a-NGR and IFN-a2a in vivo.
The anticancer activity of IFN-a2a-NGR was studied in
xenografted mice. A549 cells or SPC-A-1 cells were implanted
in mice, followed by daily i.p. administration with different doses
of IFN-a2a-NGR or IFN-a2a, as indicated (n = 8). The mice
were sacrificed and the tumor tissue was dissected. Tumor
weights of different groups of A549 (a) or SPC-A-1-challenged
mice (b). For all experiments, each group was performed in
triplicate. Data were analyzed by Student’s t test. * p\ 0.05
versus IFN-a2a groups of same doses. (c) Pictures of isolated
tumors. NO. 1–7 represents 7 treatment groups: 1. 0.9 % sodium
chloride only; 2. IFN-a2a 1 9 106 IU/kg; 3. IFN-a2a 3 9 106
IU/kg; 4. IFN-a2a 9 9 106 IU/kg; 5. IFN-a2a-NGR 1 9 106
IU/kg; 6. IFN-a2a-NGR 3 9 106 IU/kg; 7. IFN-a2a-NGR
9 9 106 IU/kg. Treatment with IFNa2a-NGR resulted in
significant reduction in tumor volume in comparison with
negative controls. In contrast, only a mild suppression of tumor
growth was noted with the IFNa2a-treated mice. Similar results
were obtained from both the A549 and SPC-A-1 implanted
groups
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irregular lumens in tumor tissues. Every drug-treated
group had a lower MVD than that of control. However,
at the same dose, IFN-a2a-NGR displayed a signifi-
cantly decreased MVDwhen compared to that of IFN-
a2a (Fig. 2c, d). Besides, CD13 was highly expressed
around the tumor vessels and the tumor tissue from
IFN-a2a-NGR treatment group showed weak staining,
whereas those from IFN-a2a treatment groups showed
stronger staining with anti-CD13 antibody and control
groups showed strongest staining (Figure S2).
IFN-a2a-NGR reduced the expression of VEGF
and bFGF
VEGF and bFGF are known as tumor-derived pro-
angiogenic factors which play a crucial role in
1044 Cytotechnology (2015) 67:1039–1050
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tumor progression. The paraffin-embedded tumor
tissues from antitumor studies were analyzed by
histology staining with anti-human VEGF or bFGF.
A marked reduction of VEGF and bFGF in tumors
treated with IFN-a2a-NGR was observed (Fig 3a,
b). As can be seen in Table 1, tissues from IFN-
a2a-NGR-treated mice displayed a greater reduction
in VEGF expression compared to that of IFN-a2a.
Similar effects on bFGF expression were observed.
Both IFN-a2a-NGR and IFN-a2a decreased the
expression levels of VEGF and bFGF in tumor
tissues compared to control mice (Table 1). This
decrease in expression was observed at all doses
except for LD (1 9 106 IU/kg) IFN-a2a. Further-
more, western blot assay also proved that IFN-a2a-
NGR was more potent in reducing VEGF and bFGF
expression compared to IFN-a2a (Fig. 3c). A real-
time PCR assay showed that there was a significant
reduction in the transcription of these two factors in
IFN-a2a-NGR- and IFN-a2a-treated cells compared
with controls, in a dose-dependent manner.
(Fig. 3d).
IFN-a2a-NGR induced apoptosis and inhibited
the migration, invasion and canaliculization
of vascular endothelial cells
To further investigate the inhibitory function of IFN-
a2a-NGR on tumor neovessels, we assessed the effect
of IFN-a2a-NGR on the apoptosis of vascular endo-
thelial cells. TUNEL analysis showed significant
apoptosis of vascular endothelial cells at 72 h after
treatment with IFN-a2a-NGR, where apoptosis in-
ductivity was 7 and 36 % at concentrations of 100 and
1,000 IU/mL, respectively. IFN-a2a showed a lower
apoptosis induction, with 4 and 15 % at concentrations
of 100 and 1000 IU/mL, respectively (Fig. 4a, b).
Tube formation was significantly decreased by treat-
ment with IFN-a2a (100 or 1000 IU/mL) or 100 IU/
mL IFN-a2a-NGR (Fig. 4c). Our migration assay
results showed that the mobility of the cells had
reduced for 13.7 % (50 IU/mL), 29.3 % (500 IU/mL)
and 37.8 % (50 IU/mL), 56.4 % (500 IU/mL) respec-
tively, after treatment with IFN-a2a or IFN-a2a-NGR
for 12 h (Fig. 4d, e). Similar findings were observed in
the invasion assays, where the values had reduced by
19.1 (50 IU/mL), 52.1 (500 IU/mL), 56.2 (50 IU/mL)
and 78.1 % (500 IU/mL), respectively, after treatment
with IFN-a2a or IFN-a2a-NGR (Fig. 4f). To evaluate
the migration ability of HUVECs in the presence of
these compounds, the migration distance of cells into
the ‘scratch’ region was measured after 36 h of
incubation. As shown in Fig. 4g, h, migration of cells
into the scratch region was markedly reduced in the
presence of IFN-a2a-NGR, indicating that IFN-a2a-
NGR and IFN-a2a can potently inhibit the migration
and mobility of vascular endothelial cells and IFN-
a2a-NGR has a stronger inhibition effect than IFN-
a2a.
Discussion
IFN therapy is used in the treatment of a number of
malignant diseases. However, this therapy is associ-
ated with significant side effects. To improve the
efficacy and reduce the adverse effects of IFN
treatment, we combined the tumor target therapy
together with IFN-a2a. NGR peptides can bind with an
aminopeptidase isoform of aminopeptidase N (APN),
also known as CD13, which is expressed in tumor
Fig. 2 IFN-a2a-NGR can selectively bind to vessels and
decrease MVD of tumor tissues. a Immunohistochemistry
detection of IFN-a2a in tumor tissue sections. 3 9 106U/kg
IFN-a2a-NGR or IFN-a2a was injected to tumor-bearing mice
i.v. The tumor tissue from IFN-a2a-NGR treatment group
showed strong staining, whereas those from negative controls
and IFN-a2a treatment groups showed weak staining with anti-
human IFN-a antibody. Shown is a representative image. b The
ELISA assay of IFN-a2a-NGR or IFN-a2a binding to microtiter
plates. The plates were coated with purified human CD13. The
ELISA assay was carried out with serially diluted IFN-a2a-
NGR or IFN-a2a as indicated. Plates were then washed and the
bound IFN-a2a-NGR or IFN-a2a was detected using an anti-
hIFN-a monoclonal antibody. The bound peroxidase was
detected by chromogenic reaction with o-phenylenediamine
after washing with DPBS. For all experiments, each group was
performed in triplicate. Data were analyzed by Student’s t test.
Points, mean (n = 3); bars, SE. * p\ 0.05, ** p\ 0.01,
*** p\ 0.001. c The detection of MVD in tumor tissues by
immunohistochemistry. Vascular density in the tumor sections
from A549-bearing mice was determined by the most intense
CD34 staining. A representative image is shown. MVD in A549
tumors treated with IFN-a2a-NGR was markedly decreased in
comparison with the control and IFN-a2a-treated tumors.
d Statistics analysis on effects of IFN-a2a-NGR and IFN-a2a
treatments on MVD in tumor tissues at different doses. Single
endothelial cells or clusters of endothelial cells positive for
CD34 staining were considered as individual vessels.
* p\ 0.05 versus control groups, ^ p\ 0.05 versus IFN-a2a
groups
b
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vessels but not in normal epithelia or myeloid cells
(Curnis et al. 2002a, b). CD13/APN has been shown to
mediate the migration and invasion of endothelial cells
in the process of angiogenesis. In previous studies, we
coupled NGR with the C-terminal of IFN-a2a (Meng
et al. 2007). The recombinant IFN-a2a-NGR was
expressed in E. coli. and was purified by ion exchange
chromatography. The preclinical safety evaluation of
IFN-a2a-NGR showed that administration of this
recombinant protein was extremely well tolerated
with very high doses in mice, rats and monkeys (Meng
et al. 2008). In the current study, we confirmed the
tumor inhibition effect of IFN-a2a-NGR in vivo and
found that it was 39 more potent than IFN-a2a in
elicting its anti-tumor effects in A549- and SPC-A-1-
bearing mice. This suggests that IFN-a2a-NGR could
increase the therapeutic index of IFN-a2a while
lowering the dose. This recombinant strategy
enhanced IFN-a2a tumor therapy and may be impor-
tant in reducing the concentration of drugs needed and
thus reducing the potential side effects caused by high
dose IFN-a2a.
Our previous study also showed IFN-a2a-NGR had
the ability to bind with the tumor vessels (Meng et al.
2007). Immunohistochemistry results confirmed the
high binding affinity of IFN-a2a-NGR to the tumor
vasculature and further demonstrated that IFN-a2a-
NGR can selectively target tumor vessels. The
Fig. 3 IFN-a2a-NGR
decreased the expression of




or IFN-a2a were obtained
from antitumor studies,
prepared and coated on
polylysine-coated slides.
The sections were stained
with the mouse anti-human-
bFGF (Santa Cruz), VEGF
(Zymed) antibodies to
examine VEGF (a) and
bFGF (b) expression in
tumor tissues. (c) Western
blot analysis of VEGF and
bFGF expression in tumor
tissues. (d) The Real-time
PCR assay of VEGF and
bFGF mRNA level in tumor
tissues. For all experiments,
each group was performed
in triplicate or
quadruplicate; the mean
value ± SD of a
representative of three
independent assays is
shown. Data were analyzed
by one-way ANOVA
statistical tests. * p\ 0.05
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aggregation of IFN-a2a-NGR in tumor tissue was
significantly more elevated than that in IFN-a2a-
treated group after intravenous injections for 30 min,
suggesting that IFN-a2a-NGR effectively improves
the tumor targeting ability of IFN-a2a and raises the
drug concentration in tumor tissues, and thereby
increasing the anti-tumor effects in vivo.
It has been demonstrated that angiogenesis is
crucial for tumor migration and invasion. The density
of newly formed micro-vessels in tumors is closely
correlated with an increase in the volume of tumors
(Poon et al. 2002). In this study, we found that the
MVD of tumor tissues in the IFN-a2a-NGR therapy
group was less than that of the control and IFN-a2a-
treated groups. The findings further showed that IFN-
a2a-NGR has more powerful anti-tumor effect than
IFN-a2a, possibly due to the tumor vessels targeting
property of IFN-a2a-NGR contributing to the accu-
mulation of IFN-a2a-NGR in tumor and enhancing the
anti-angiogenesis of IFN-a2a. We speculated that
NGR binding to APN might block the function of
APN, which in turn contributed to the anti-angiogen-
esis of IFN-a2a.
VEGF is a vascular permeability factor responsible
for the characteristic leakiness of tumor blood vessels
and is also an important growth factor with angiogenic
activity (Nagata et al. 2002). bFGF, known as an
endothelial cell survival factor, is an important
regulator of endothelial cell proliferation, migration,
and protease production (Edelman et al. 1992). We
found that IFN-a2a-NGR could down-regulate the
expression of VEGF and bFGF, thus decreasing the
levels of angiogenesis and contributing to an inhibi-
tion in tumor growth.
To investigate whether the decrease in MVD of
tumor tissues resulting from IFN-a2a-NGR was
associated with an increase in endothelial cell apop-
tosis, we performed TUNEL staining of HUVEC cells
and found that IFN-a2a-NGR treatment significantly
induced apoptosis at a higher rate than IFN-a2a. This
may be due to the specific affinity of NGR to vessel
endothelial cells. The tumor vessels targeting property
of IFN-a2a-NGR conjugates may therefore contribute
to the anti-angiogenesis effect.
Other characteristics of angiogenesis include the
breakdown of the basal membrane, endothelial cell
proliferation, migration and tube formation. IFN-a2a-
NGR or IFN-a2a treatment displayed inhibition in
endothelial cells migration, invasion and tube forma-
tion. In addition, the inhibition achieved with IFN-
a2a-NGR treatment was better than that of IFN-a2a, at
the same doses. These findings revealed that IFN-a2a-
Table 1 The expression level of VEGF and bFGF in tumor tissues of tumor-bearing mice
Groups n VEGF Positive ratio (%) bFGF Positive ratio (%)
- ? ?? - ? ??
Control 24 2 5 17 91.7 2 4 18 91.7
1 9 106U/kg
IFN-a2a
24 3 10 11 87.5 3 9 12 87.5
3 9 106U/kg
IFN-a2a
24 5 11 8 79.2* 7 7 10 70.8*
9 9 106U/kg
IFN-a2a
24 9 12 3 62.5* 9 10 5 62.5*
1 9 106U/kg
IFN-a2a-NGR
24 8 10 6 66.7*^ 9 12 3 62.5*^
3 9 106U/kg
IFN-a2a-NGR
24 14 6 4 41.7*^ 10 12 2 58.3*^
9 9 106U/kg
IFN-a2a-NGR
24 17 7 0 29.2*^ 14 9 1 41.7*^
Negative (-) indicates that no positive cells were founded in tumor tissue sections. Weak positive (?) indicates a positive ratio
between 0 and 50 %. Strong positive (??) indicates a positive ratio[50 %. Data were analyzed by v2 tests in the SPSS statistical
package. Differences were considered significant when the p value was\0.05
* p\ 0.05 versus control groups, ^ p\ 0.05 versus IFN-a2a groups
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NGR is a more powerful anti-angiogenic agent than
IFN-a2a. In conclusion, IFN-a2a-NGR has the ability
to effectively target tumor vessels and then inhibit
endothelial cell tube formation, migration and inva-
sion through an induction in apoptosis and decreases
in the expression of VEGF and bFGF.
The differences in effects that we observed with
IFN-a2a-NGR compared to IFN-a2a may be due to
the presence of the NGR motif. When Curnis et al.
(2000) fused the NH2 terminus of TNFwith the COOH
terminus of peptides containing the NGR motif, the
resulting NGR-hTNF conjugate could specifically
bind with CD13, which is required for the develop-
ment of tumor vessels. Administration of very small
amounts of NGR-TNF was sufficient to enhance the
antitumor activity (Curnis et al. 2002a, b). The binding
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of NGR-hTNF to endothelial cells elicits defined
signaling pathways through both TNF receptors and
CD13, which result in cell death by impairing survival
and promoting apoptosis. Ellerby et al. (1999) fused
CNGRC with a pro-apoptotic peptide to form a new
therapeutic agent which showed selective toxic to
angiogenic endothelial cells and anti-cancer activity in
mice.
Our study shows that the treatment with IFN-a2a-
NGR was successful and more efficacious compared
to that of IFN-a2a, with its ability to target tumor
vessels while preserving the original function of IFN-
a2a. The tumor blood vessel ‘homing’ peptide NGR
has also been demonstrated to function as targeting
elements which served to improve the binding
efficiency of HUVEC cells in gene delivery (Liu
et al. 2000). CD13 by itself can directly lead to a
highly selective homing on tumor blood vessels and
apoptosis of angiogenic endothelial cells in vivo, thus
significantly contributing to the control of tumor
growth and accelerating the tumor angiogenesis
inhibiting effect. Studies demonstrated that IFN-a
treatment can induce impressive MVD reduction and
tumor growth inhibition (von Marschall et al. 2003). It
was reported that these anti-angiogenic activities of
IFN-a associated with the regulation of endothelial
cell motility and survival and with inhibition of
molecules involved in the angiogenic response, such
as VEGF and bFGF (Singh et al. 1995; Albini et al.
2000; Sgonc et al. 1998). NGR may contribute to the
endothelial cell motility inhibition and apoptosis
induced by IFN-a through facilitating the binding of
IFN-a to HUVEC cells which express high levels of
CD13 in response to growth factors in the culture
medium (Mina-Osorio et al. 2008). Therefore, both
NGR and IFN-a2a portions contribute to the biolog-
ical activity of IFN-a2a-NGR vascular targeting agent
in vivo. The binding of NGR to CD13 may not only
lead to the homing of IFN-a2a-NGR but also stabilizes
the NGR-CD13/IFN-IFNR interaction. The signaling -
pathways by which IFN-a2a-NGR elicits its effects
still require further elucidation. Our findings from
in vitro and in vivo experiments indicated that IFN-
a2a-NGR is a promising anti-angiogenic agent with
more significant therapeutic efficacy and lower toxic-
ities than IFN-a2a.
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